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Antibiotic resistance is an inevitable by-product from treatment of bacterial (and 
fungal) infections, however the rate and intensity at which it is emerging is 
alarming. More and more drugs are being rendered ineffective, where poor 
treatment behaviours, such as overuse, are being held accountable. Coupled 
with a dry antibiotic pipeline, we are increasingly seeing ourselves approach a 
post-antibiotic era. As research is being conducted into discovering new 
antibiotics, we also need to find ways to preserve the ones we still have. 
Therefore it is equally important to identify and study potential selection 
pressures, both environmental and clinical, that contribute to the rise in 
resistance.  
 
To provide a preliminary insight on temperature as a possible selection 
pressure, this research project aimed to investigate the effect of temperature on 
the susceptibility of Escherichia coli to the macrolide-class antibiotic 
erythromycin, and ultimately its effect on the expression of multidrug efflux 
pump AcrAB-TolC. This was done by exposing E. coli cells to a range of 
erythromycin concentrations during 24 hours of growth, establishing a minimum 
inhibitory concentration (MIC) at 30oC and seeing any shifts in the MIC at 37oC. 
It was found that as temperature increased from 30oC to 37oC, so did the MIC. 
Thus the cells were more resistant at the higher temperature.  
 
Next, to see whether and how AcrAB-TolC was selected for as a result of 
temperature, the expression of protein AcrB was measured via fluorescence 
emitted from sfGFP (due to the sfGFP gene being physically fused to the acrB 
gene). It was found that the range of concentrations that select for pump 
expression, referred to as the “AcrB expression-selection window”, shifted 
positively with increasing temperature. This suggests a temperature-dependent 
nature of resistance selection, therefore this knowledge may help in choosing 
an effective dose for treatment based on thermal conditions. 
 
The outcomes of this research project will help provide a foundation for looking 
further into temperature, and other selection pressures, and their effect on the 
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Chapter 1 – Introduction 
 
Antibiotics, considered one of the greatest discoveries in the history of modern 
medicine, are a group of drugs used for treating infections caused by bacteria 
as well as fungi. First discovered in the 1940s, their misuse, such as being 
widely prescribed and over-used in treatment and in maintaining livestock, has 
contributed to the rapid emergence and spread of resistant strains of bacteria 
globally [1, 2, 3]. This is termed as antibiotic resistance, a current pandemic 
that, according to the World Health Organisation (WHO), needs to be a high 
priority in research to prevent disruption on progress in public health and food 
security [1]. As a consequence, this increased rate of emergence has led to 
longer durations of hospitalisation, higher medical costs and mortality rates, as 
even common infections are becoming increasingly difficult to treat [1, 2, 3]. For 
instance, a study conducted in the European Union (EU) found that between 
2007 and 2015, the average incidence of infections caused by a selected group 
of resistant bacteria (commonly found in blood diseases) increased from 
239,288 to 602,609 cases. In 2007, approximately 25,000 deaths and 2.5 
million extra hospital days were attributed to the resistant infections, contributing 
to an overall extra medical cost of EUR 900 million. In 2015, however, the 
number of deaths increased to 33,000 [4, 5]. 
 
It should be noted that antibiotics have always existed in nature, produced by 
some microbes as a means of subduing competitors in an ecological niche, the 
same compounds that we exploit today in the clinic. As a result of the existence 
of this artillery in the environment, many competitors have evolved resistance 
over time to tackle the toxic compounds. This particular type of pre-existing 
antibiotic resistance is known as intrinsic resistance [6, 7]. However, the type 
that is of major public concern nowadays is acquired resistance. As the name 
suggests, this is when previously-susceptible cells acquire defence 
mechanisms by either taking up resistance-containing genetic material e.g. 
plasmids from other bacterial cells or the environment, or undergoing a 
spontaneous mutation or overexpressing a particular gene(s) as a response to 
a selection pressure [7]. Poor treatment behaviours such as over-use are one of 
many factors contributing to speeding up the process as well as amplifying the 
level of acquired resistance [1, 2, 3, 4]. 
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To tackle the rate at which antibiotic resistance is emerging, plans of action 
have been suggested by organisations such as WHO, the Centre for Disease 
Control (CDC) and the European Centre for Disease Prevention and Control 
(ECDC) along with scientists established in the field of drug resistance. The 
general consensus agreed on measures such as public education on 
behaviours that lead to resistance, prevention strategies, strict control over 
antibiotic use and looking into finding new antibiotics and/or alternatives (e.g. 
antibacterial vaccines) [1, 4, 8, 9]. The discovery of new antibiotics, however, 
has proven to be significantly difficult, and thus no new class has been 
introduced in the clinic in the last few decades. This is mainly due to exhausting 
the available resources from where antibiotics can be cultivated, such as soil 
[10, 11]. Ultimately, this has led to the rate of the loss of effective antibiotics (as 
a result of developing resistance) surpassing the rate of novel antibiotic 
discovery. In other words, this slow and limited supply of antibiotics is struggling 
to meet the increasingly high demand for them [12]. Only relatively recently has 
the potential antibiotic, termed “teixobactin”, been discovered, but it still has yet 
to undergo clinical trials before its release to the wider public [12, 13].  
 
Another critical concern is that any new antibiotic discovered will inevitably 
suffer the same fate of resistance development befallen to previous ones. 
Therefore, not only is discovering new antibiotics important, but the way we use 
our current and future ones is equally just as important. Along with present-day 
implemented control actions such as using narrow-spectrum antibiotics during 
treatment (as opposed to broad-spectrum) that are more specific to the causal 
pathogen, and opposing unnecessary prescribing of antibiotics in the clinic [2, 3, 
8, 9], we need to find better and more effective ways to preserve the ones we 
already have. This can only be achieved by studying and defining selection 
pressures that lead to the increased rate of resistance. 
 
Generally speaking, selection pressures, as the name suggests, are conditions 
or factors that when applied select for a favourable trait and gradually its fixation 
within a population i.e. the trait becomes more common over time. Charles 
Darwin explained in his publication “On the Origin of Species” that when 
exposed to such pressures, the variations in characteristics observed within a 
population play a critical part in survival [14]. Those individuals that have a more 
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favourable phenotype (or genotype) to the current environmental condition may 
survive, reproduce and pass on such traits to their progeny, whilst the 
individuals with the least desirable traits will be, according to Darwin, “rigidly 
destroyed” by the change in condition i.e. the ill-suited phenotype will gradually 
cease to exist. It is this phenomenon, termed “natural selection”, which leads to 
the evolution of species [14].  
 
Although based on animals and plants, Darwin’s observations can also be seen 
amongst bacteria, a prime example being acquired resistance in the clinic. 
During a course of treatment, the bacterial population is exposed to a harsh 
antibacterial environment. Amongst the cells, individuals that express some 
form of resistance to the drugs used during the treatment (as a result of 
accumulating random mutations and/ or genetic material) are able to reproduce 
and pass on this favourable genotype. With prolonged exposure including 
attempts to treat with higher doses, amplification in the level of resistance and 
the genotype fixating itself within the population may eventually occur, gradually 
rendering the treatment drug(s) useless [15].  
 
As mentioned previously, the use of antibiotics in treatment is just one of 
several other selection pressures that come together to play a part in the 
observed increased rate of emerging resistance seen globally. Some of these 
potential pressures, i.e. exposure to low concentrations of antibiotics that exist 
within the environment, motility in a spatially complex environment and the 
presence of other toxic compounds will be looked into further in this chapter, 
with special emphasis on temperature throughout the report as this is the main 












1.1 Mechanisms of Resistance 
 
There are different types of mechanisms bacteria can deploy to protect 






One method is by enzymatically altering or degrading the drug molecule so that 
it can no longer bind to its target in the bacterium [7, 17]. An example of this is 
seen in penicillin resistance provided by β-lactamase enzymes [18, 19]. These 
enzymes render β-lactam antibiotics, such as penicillin, ineffective by cleaving a 
part of the drug. The spread of penicillin resistance was found to be due to β-
lactamase-encoding plasmids being transferred between bacteria [19]. To 
tackle the action of these enzymes, research is being conducted in three areas: 
the production of synthetic antibiotics with an altered or removed enzyme-target 
region, inhibitor molecules to bind and block the enzyme active site, and 
improving the delivery of drugs to the corresponding targets in the bacterium 
[20]. 
 
A second method of resistance involves altering the drug target, either by a 
mutation occurring in one or more of its associated genes, chemical 
modification of the components, or protecting the target to prevent access so 
Figure 1.1: A schematic of the four mechanisms of antibiotic resistance within a bacterial 
cell taken from reference 16. Efflux pumps, shown in the top left corner (purple), are the 







This image has been removed by the author of this 
dissertation for copyright reasons. 
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that the antibiotic molecule is no longer able to bind and carry out its function [7, 
17]. A well-studied example is tetracycline resistance mediated by the ribosomal 
protection proteins (RPPs) Tet(O) and Tet(M). The antibiotic tetracycline binds 
to bacterial ribosomes, interfering with protein synthesis and thus preventing 
microbial growth and viability. To circumvent this, the RPPs, as their name 
suggests, protect the ribosome by dislodging the bound drug so that protein 
synthesis can resume [21]. Tet(M) specifically has been found on conjugative 
transposons, which are mobile genetic elements similar to plasmids but are able 
to integrate and excise themselves into and out of the bacterial genome. In 
addition, conjugative transposons are able to be transferred between different 
bacterial species, contributing to the wide dissemination of antibiotic resistance 
[22, 23]. One way to overcome target protection is to develop antibiotics that are 
able to bind more effectively to the target, preventing their removal. In the case 
of Tet(O) and Tet(M), glycylcyclines are able to stay bound to the ribosome 
even in the presence of the RRPs [24].  
Another option is the use of combination therapy in which more than one drug 
are used that a) enhance the potency and action of the antibiotic(s), and/or b) 
bind to different target sites in the pathogen to overcome the effect of resistance 
mechanisms [25]. For example, tetracycline is commonly used in combination 
with the antibiotic metronidazole and other compounds as second-line treatment 
in Helicobacter pylori infections, where both antibiotics work synergistically to 
eradicate the bacteria [26, 27]. However, it should be noted that in some 
developing areas the above drug combination may fail, such as in Shanghai in 
the People’s Republic of China, where tetracycline and metronidazole-
resistance is prevalent [27, 28]. Interestingly, a study had shown that the 
genotypes of H. pylori varied between isolates all over the globe [29], which 
may suggest a variation in the selection pressures they are exposed to. This 
again highlights the importance of studying these conditions in order to tailor 
specific therapies that are effective in treatment, all whilst reducing the impact 
on the rate of antibiotic resistance emergence. 
 
A third defence mechanism against antibiotics is by bacteria reducing the 
permeability of their cell wall so that the drug is not able to gain access to its 
target [7, 17]. The cell surface of Gram-positive bacteria contain a lipid bilayer 
membrane coated by a thick layer of peptidoglycan. Lipids in this arrangement 
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create a hydrophobic layer which many molecules may struggle to bypass, 
particularly if they are large and/ or hydrophilic like many antibiotics. In addition, 
Gram-negative bacteria have another lipid bilayer surrounding their relatively-
thin peptidoglycan layer, providing an extra level of intrinsic resistance by 
further restricting the movement of molecules. This outer-membrane also 
contains protein channels known as porins, allowing the movement of small 
hydrophilic molecules in and out of the cell [30, 31]. However, the bacterium 
may reduce the expression of these surface proteins or lose them altogether to 
further reduce membrane permeability [7, 17, 31]. To tackle this, antibiotics can 
be coupled with membrane permeabilisers such as polymyxin antibiotics as part 
of combination therapy to allow penetration of the main drug into the cell and/ or 
eventual cell lysis [32]. However, polymyxin-resistant strains of Escherichia coli 
and Salmonella typhimurium have been isolated [32]. In fact, the polymyxin 
drug colistin had always been considered as a last-resort antibiotic for 
multidrug-resistant (MDR) infections. However recently incidences of colistin 
resistance have risen at an alarming rate in many parts of the world, attributed 
to a plasmid-mediated spread of the resistance gene [33, 34, 35, 36, 37, 38]. 
Therefore it is important for future studies to look into how this resistance 
occurs, and the development of more effective membrane permeabilisers that 
are less likely to have resistance develop against them. 
 
Efflux pumps, the fourth defence mechanism, are a good example of both 
intrinsic and acquired resistance, as they are constitutively expressed at a basal 
level in some bacteria, but can be overexpressed as a response to the 
environment [6, 39]. They are proteinaceous transporters that are found on the 
cell membrane of different organisms from different domains of life [40, 41], 
including humans [42, 43] as well as bacteria, with the purpose of expelling 
toxic substances from within the cell into the environment where it will cause 
less harm. These toxic substances include those produced by the cell as a 
result of metabolism, as well as competitor-produced antibiotics [6, 39]. 
Discovered in the 1980s, the study of efflux pumps is steadily creeping into the 






1.1.1 Efflux Pumps 
 
Prokaryotic pumps can be divided into families based on certain criteria such as 
their structure, components and sequence, the substrates they utilise and their 
source of energy [44, 46] (Fig. 1.2).  
 
The adenosine triphosphate (ATP)-binding cassette (ABC) superfamily, as the 
name suggests, depends on ATP as its energy source to actively transport 
molecules out of the cell [47]. Interestingly, the first reported bacterial ABC 
efflux pump was found in Lactococcus lactis, specifically discovered through 
homologous-linking with the human ABCB1 efflux pump known to be involved in 
chemotherapy resistance [48]. The Multidrug and Toxic Efflux (or Multidrug and 
Toxic compound Extrusion) family (MATE), also found amongst many 
organisms e.g. NorM in Vibrio parahaemolyticus, are a group of Na+/ drug 
antiporters where compounds such as fluoroquinolones are expelled in 
exchange for Na+ [49].  
 
The Major Facilitator Superfamily (MFS), one of the largest groups that are 
mainly found in Gram-positive species, are also antiporters but instead import 
H+ ions, and therefore take advantage of the proton motive force to provide 
energy to export compounds out of the cell [50]. One of the first examples and 
of clinical relevance is the pump QacAB found in Staphylococcus aureus, 
discovered to be plasmid-mediated through many incidents of highly-resistant 
hospital-acquired infections [51]. The Small Multidrug Resistance (SMR) family 
also utilise the energy provided from the movement of protons but are relatively 














Of all the classes, the Resistance Nodulation and cell Division (RND) 
superfamily, found mostly in Gram-negative bacteria, may be deservingly 
considered the most extensively studied due to their paramount role in drug-
resistant infections caused by clinically-relevant pathogens [44, 45]. Pumps of 
this group mainly form tripartite complexes, consisting of components in the 
inner membrane, the periplasmic space and the outer membrane coming 
together, and using the proton motive force to undergo a conformational change 
and expel toxic compounds from within the cell [44]. A clinically important 
example of such an efflux pump, and the specific subject of this research study, 









Figure 1.2: An illustration of the five major families of efflux pumps found in the prokaryotic kingdom, 
taken from reference 46. The Resistance Nodulation and cell Division (RND), Small Multidrug 
Resistance (SMR), Major Facilitator (MFS), Multidrug and Toxic Efflux (MATE) and Adenosine 





AcrAB-TolC consists of the trimeric inner-membrane RND transporter AcrB, the 
periplasmic hexamer adaptor protein AcrA, and the trimeric outer-membrane 
channel TolC [53] (Fig. 1.3A). The substrate binds to a drug-binding pocket 
within a vestibule formed by AcrA and AcrB in the periplasm, and via a 
rotational mechanism of the whole protein complex, is actively pumped out of 
the cell using the energy supplied by the movement of protons across the inner 
membrane [39, 54] (Fig. 1.3B). In E. coli, AcrAB-TolC has also been shown to 
associate with AcrZ, a small component found to modulate some of the 





Due to its non-specificity, AcrAB-TolC is able to bind to a wide range of 
substrates with very little similarity between them. Thus this efflux pump is 
directly attributed to MDR [56]. As well as being constitutively expressed in E. 
coli, AcrAB itself is found across a diverse range of Gram-negative species 
such as Salmonella [57], Klebsiella pneumoniae [57, 58], Enterobacter cloacae 
[59] and Yersinia enterolitica [60], where its functionality has remained fairly the 
same. Homologous complexes related to AcrAB-TolC can also be found 
coexisting within E. coli itself (e.g. CusA-CusB which is involved in heavy-metal 
Figure 1.3: A) A pseudo-atomic model of the structure and arrangement of the efflux pump AcrAB-
TolC in association with AcrZ (taken from reference 53) and B) A diagram representing the 
hypothesised mechanism by which substrates are extruded by the efflux pump into the extracellular 




expulsion) [39, 61], as well as in other organisms such as MexAB-OprM in the 
plant pathogen Pseudomonas aeruginosa [57, 62]. A distant relative of 
transporter component AcrB also exists within the eukaryotic kingdom, known 
as Niemann-Pick C1 (NPC1), and is involved primarily in cholesterol efflux. In 
humans, mutations in the npc1 gene is known to cause Niemann-Pick disease 
type C (NPC), a rare neurodegenerative condition due to the accumulation of 
cholesterol and other lipids in the brain, liver and spleen [63]. 
 
The role of AcrAB-TolC in MDR and its homology to efflux pumps in other 
organisms makes the complex a prime target for research. The importance of 
researching AcrAB-TolC has been demonstrated from recent studies. 
Although some of these studies have shown mutations occurring in AcrAB-TolC 
and levels of expression of the pump increasing with antibiotic exposure at the 
transcriptional and translational level [64, 65, 66, 67, 68], the morbid reality of 
AcrAB-TolC was demonstrated by one particular study. It was observed in this 
study that during a clinically-approved antibiotic treatment course for a 
Salmonella infection, post-treatment Salmonella enterica serovar Typhimurium 
strains isolated from a patient had been shown to contain a single amino acid 
substitution in the drug-binding pocket of AcrB, in comparison to the pre-
treatment strain [66]. Specifically, glycine (G) was substituted for aspartic acid 
(D) at residue 288 (Table 1.1), altering the affinity for certain drugs such as 
ciprofloxacin and nalidixic acid, specifically leading to increased efflux of these 
two molecules. This was shown to occur within 3 weeks of being on 
ciprofloxacin treatment, where the substitution was maintained even when the 
treatment course had progressed onto the antibiotics ceftazidime and 
aztreonam [66].  
 
Table 1.1: Amino acid substitutions in residue 288 of AcrB in MDR strains of Salmonella isolated 
from a patient at different times during antibiotic therapy (taken from reference 66). Post-therapy 
strains (from L12 onwards) show G288D substitution in AcrB in comparison to pre-therapy strain 
L3 (red box). 
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Therefore, in this situation, the presence of a drug selected for the amino acid 
substitution in order to allow the bacteria to adapt to their hostile environment 
[66]. It was also believed that due to the substitution, expression of acrB 
doubled in the post-therapy isolates as a consequence. Nonetheless, the amino 
acid substitution coupled with the increased expression of acrB was concluded 
to have made the infection increasingly difficult to treat, ultimately leading to the 
patient’s death [66, 67].  
 
Another study confirmed, through sequencing of E. coli lab strain eTB108 under 
different doses of the antibiotic erythromycin, that the double expression level 
can be attributed to the duplication of the acr operon (which contains acrA and 
acrB). This occurred within as little as three days under drug exposure [68].  
 
Due to its bacteriostatic nature and being a substrate of AcrAB-TolC [68, 69, 
70], erythromycin was used as the antibiotic of choice in this research project to 








Figure 1.4: Schematic of a macrolide molecule e.g. erythromycin bound to the peptide exit 
tunnel. The nascent protein is blocked from exiting the ribosome. Image taken and adapted 
from reference 69. 




Erythromycin, a macrolide-class antibiotic discovered in 1952 [71], is used in 
the treatment of a range of ailments and major illnesses, from acne to 
pneumonia and sexually transmitted infections [72]. A clinically relevant 
translational inhibitor that is effective against Gram-positive as well as Gram-
negative bacteria (and a few other non-bacterial pathogens), it acts by 
reversibly binding to the 23S ribosomal RNA (rRNA) in the larger 50S subunit of 
the ribosome, blocking the exit of the polypeptide (Fig. 1.4). This causes 
interference with elongation of the protein chain and thus the release of a 
truncated polypeptide, where higher concentrations of erythromycin can lead to 
a bactericidal effect [73, 74].  
The first reported case of erythromycin resistance was discovered in the UK in 
1959, only a few years after discovery of the antibiotic [75]. As cases rose in 
other parts of the world [76, 77], a study in Finland determined a positive 
correlation between frequent erythromycin use in the clinic and the rate of 
incidence of resistant infections [77]. It should be noted that as well as efflux, 
erythromycin resistance is also mediated by modification of the ribosome [78], 
which is beyond the scope of this research project. 
 
To overcome the resistance provided specifically by efflux pumps in clinical 
treatment, three possible steps were suggested in a research article: 1) 
remodelling old antibiotics to reduce their affinity to the binding sites of the efflux 
pump 2) increasing antibiotic uptake by modifying the membrane barrier and 
reducing efflux through channel blockers and 3) wasting energy sources for 
efflux with the use of compounds that interfere with energy production 79]. 
However, the first step may prove to be difficult. This is because evidence has 
shown, and as stated previously, new antibiotics may eventually succumb to 
resistance. Although old drugs are being remodelled, the aim of remodelling is 
to create a new structure to overcome resistance mechanisms. It is therefore 
highly likely that resistance will also develop against the transformed antibiotics 
as a result of clinical and environmental factors. In other words, through a lack 
of understanding of these factors, step 1 would prove useless. The same may 
also be said for the use of channel blockers as stated in step 2. It is important, 
firstly, to identify selection pressures and how they come together to optimally 
select for resistance. This knowledge can then be used to guide antibiotic 
design in order to treat patients successfully all whilst maintaining the efficacy of 
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current and future antibiotics and reducing the footprint on resistance evolution. 
Examples of possible selection pressures that may influence the emergence of 
antibiotic resistance are discussed below. 
 
1.4 Examples of Selection Pressures 
 
1.4.1 Low Environmental Antibiotic Concentrations 
 
One of the factors that has been identified as a potential selection pressure is 
the low-level presence of antibiotics that exist within the environment [80, 81]. 
Antibiotics can end up in the environment in many ways; through agricultural 
use and unavoidably human urine and faeces [82]. This presence has been 
shown to be an insidious force whereby through the selection of low-level 
resistance, compensatory mutations may occur to reduce the fitness cost over 
time, eventually leading to high-level clinical resistance [80].  
One particular study showed that even at extremely low antibiotic 
concentrations (similar to those found in aquatic environments and soil) E. coli 
and S. typhimurium  resistant mutants were selected for within their own mixed 
population of resistant and wild-type cells [81]. Specifically, for antibiotic 
concentrations ranging below the minimum inhibitory concentration (MIC), that 
is, the lowest concentration of antibiotic that inhibits bacterial growth, the 
research aimed to deduce a selection coefficient i.e. the strength of selection on 
resistant mutants. Strength was quantified by the change in ratio of resistant: 
susceptible cells over 80 generations of growth. In other words, the greater the 
increase in ratio over time, the higher the selection coefficient. When the 
selection coefficient was zero, the study defines the corresponding antibiotic 
dose as the minimum selective concentration (MSC) i.e. the lowest 
concentration at which the resistant mutant is selected due to the fitness cost 
being balanced by the selective force of the antibiotic concentration [81]. In a 
mixed population of wild-type and tetracycline-resistant S. typhimurium cells, 
the MSC was found to be 15 ng/ mL of tetracycline, 1/100 of the MIC (1.5 µg/ 
mL). In the case of E. coli and ciprofloxacin resistance, the MSC was 100 pg/ 
mL for ciprofloxacin, 1/230 of the MIC (0.023 µg/ mL). In addition, it was 
observed that within a population of only wild-type S. typhimurium exposed to ¼ 
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of the MIC associated with streptomycin, de novo resistant mutations occurred 
and proliferated within 200 – 400 generations [81]. 
 
1.4.2 Motility and Environmental Heterogeneity 
 
In a complex environment, such as the highly-compartmentalised human body, 
antibiotic levels are not always uniform, therefore selective concentrations may 
also exist after antibiotic consumption. Gradients tend to exist, where 
concentrations decrease when moving further away from the site of drug 
deployment [83]. A study used a microfluidic device in order to mimic such 
spatially heterogeneous environments [84]. This device contained several wells 
attached by small tunnels placed in a ciprofloxacin gradient created using Luria-
Bertani (LB) broth as the nutrient source. The study found that de novo 
ciprofloxacin-resistant mutants arose from as little as 100 wild-type E. coli cells 
when they were placed in the antibiotic gradient. It was seen that mutant 
bacteria were able to quickly move to wells of higher ciprofloxacin where they 
fixated and divided. These specific points were referred to as “Goldilocks points” 
as they contained the optimal environment for resistance (i.e. fewer bacterial 
cells and thus a high nutrient concentration) [84]. Similar results have been 
seen in chemotherapy resistance [85]. 
 
1.4.3 Heavy Metals 
 
Not always does antibiotic resistance and its spread arise as a result of direct 
antibiotic exposure, but can also occur due to the presence of other toxic 
compounds and heavy metals [86, 87, 88]. This is due to either the co-
localisation of the antibiotic resistance genes and toxin-efflux genes, or cross 
reactivity of the resistance mechanism itself where it is able to bind to non-
antibiotic molecules [89]. In fact, a study had shown that AcrAB increases in 
expression in the presence of bile-salts and fatty acids, compounds that E. coli 
cells commonly encounter in their normal environment of the intestinal tract. 
Specifically, they found that the compounds bind to acr regulator Rob, which in 




One of the least understood environmental conditions and potential selection 





Temperature variations occur everywhere, from one place to another around 
the globe, to changes in season and even in different areas of the human body 
[91, 92]. Climate change i.e. the shift in global weather patterns as a result of 
forces including greenhouse gases and aerosols, has led to consequences 
such as increased temperatures, sea levels and changes in rainfall patterns, 
and has affected not only the environment but the organisms that reside within it 
[93, 94]. According to WHO, the effects of climate change, such as increased 
rainfall, are contributing to the spread of disease [95]. Only until very recently, 
however, have the direct effects of the rise in temperature on antibiotic 
resistance been noticed. Using a large database containing records on isolates 
of pathogens K. pneumoniae, E. coli and S. aureus in different parts of the US 
and mapping them to the local climate, a study showed that regions of higher 
temperature and population density were linked to a higher fraction of 
pathogens failing to respond to first-line antibiotics. Therefore it is believed that 
the trend and burden of emerging antibiotic resistance may be underestimated 
as factors like climate change are not taken into account [96]. 
 
Although the authors were not able to elucidate the exact mechanism of the 
observed increase in incidence of resistance, they provide a few relevant 
theories and possible explanations. One of them stems from the outcome of a 
few studies which shows that with temperatures between 25oC – 37oC, 
particularly at 30oC, the rate of horizontal gene transfer is relatively high [97, 98, 
99]. In fact, recent reports of cases of plasmid-mediated resistance have 
occurred in countries that average around this temperature range [33, 98]. They 
also suggest that since temperature affects bacterial growth rates [100], this 
may also lead to the higher incidences of resistant infections [96]. 
 
When temperature is increased, the growth rate of bacteria also increases. 
Once the optimum temperature is reached e.g. 37oC for some human 
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pathogens such as E. coli, the growth rate is at its highest. Thereafter, higher 
temperatures start to inhibit proliferation [100]. The growth rate of a microbe has 
been shown to effect the overall gene expression, as some of the machinery 
required, such as ribosomes and RNA polymerases, have been shown to be 
growth rate-dependent [101]. In fact, levels of acrAB [102] and tolC [103] 
expression have also been shown to be growth-rate dependant, where in 
slower-growing cells, higher expression levels have been measured. 
 
Growth rate has been shown empirically to affect susceptibility [104, 105]. A 
study found that slow-growing cells are more sensitive to some ribosome-
targeting antibiotics, but this was largely based on how the drugs bound to their 
target. By manipulating the nutrient level to control the growth rate, it was found 
that streptomycin and kanamycin, which irreversibly bound to the ribosome, 
inhibited the growth of slow-growing E. coli at lower drug concentrations in 
comparison to tetracycline and chloramphenicol, which reversibly bound [104]. 
The opposite was also seen in fast-growing E. coli, where tetracycline and 
chloramphenicol had the most effect. In other words, slow-growing cells were 
more susceptible to antibiotics that bound irreversibly to the ribosome [104]. 
Although not a ribosome targeting antibiotic, another study had shown that 
slower growing E. coli cells were, in contrast, less susceptible to β-Lactam 
antibiotics [105]. 
 
It should be noted that, in most of the aforementioned studies, the growth rate 
was controlled by nutrient levels. It would be interesting to see if growth rate 
controlled by temperature produces similar outcomes. This research project 
provides a preliminary insight on the matter. 
 
As well as growth rate and the type of drug, different bacterial species respond 
differently to temperature variations. Studies have shown that by increasing the 
temperature, S. aureus becomes increasingly sensitive to tetracycline and 
penicillin [106, 107]. In another experiment it was shown that elevated 
temperatures, even in the absence of rifampicin, led E. coli strains to develop 
rifampicin resistance [108]. In the case of S. aureus, it was because of the loss 
of resistance genes and for E. coli, a mutation in a gene encoding a component 
of RNA polymerase [106, 107, 108]. 
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Temperature has also been shown to affect many other aspects of the bacterial 
cell such as metabolism [109], motility [110], mutation rates [111] and cell shape 
[112].  
 
It should be noted that when bacteria are suddenly exposed to colder or warmer 
temperatures than their optimal, this is known as cold shock and heat shock 
respectively. As a result of these temperature extremes, microbes synthesise 
proteins, termed heat shock proteins (HSP) and cold shock proteins (CSP) (at 
around 42oC+ and 15oC- respectively in mesophiles) in order to protect 
themselves [113]. One would assume that there is a fitness cost associated with 
expressing such genes, and thus in turn affecting the expression of resistance 
genes. Interestingly, heat shock proteins have been found to actually decrease 
susceptibility in some studies [114, 115]. For example, a study in cancer cells 
showed that the resistance of some tumours to chemotherapy were as a result 
of the increased expression of HSP27 (Heat Shock Protein 27). The exact 
mechanism is unknown, but the authors speculate that HSPs interact with cell 
cycle proteins, enhancing cell division [114]. HSPs have also been found to 
affect the antibiotic susceptibility of bacterial strains. One such example is the 
HSP ClpL in Streptococcus pneumoniae. ClpL has been shown to influence 
enzymes involved in cell wall construction, resulting in reduced sensitivity to 
penicillin [115]. However this particular research project will not look at extreme 
temperatures, but consideration of HSPs and CSPs will be important in any 
future experiments that may work with such temperature ranges. 
  
Apart from the differential expression of acr genes at different growth rates, 
literature on the effect of temperature on efflux pumps is extremely limited. One 
study showed that expression of the efflux pump system RosA-RosB, providing 
Y. enterolitica with resistance to cationic antimicrobial peptides (CAMPs), 
occurred at room temperature and 37oC, but only in pathogenic strains [116]. 
Pump expression in non-pathogenic strains was induced only at room 
temperature, and repressed at 37oC. The researchers were unable to explain 
the repression empirically but hypothesise that RosA-RosB may have another 
role other than providing CAMP resistance in non-pathogenic Y. enterolitica 
[116]. Therefore it would be interesting to see what the relationship of AcrAB-
TolC expression is with temperature. 
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1.5 Project Aims 
 
Based on the aforementioned studies, it is hypothesised that an increase in 
temperature will have an effect on the susceptibility of bacteria to antibiotics. 
Therefore, the overall aim of this research project is to investigate the effect of 
increasing temperature on pump-mediated antibiotic resistance displayed by E. 
coli towards erythromycin. To test this hypothesis, relevant strains of E. coli will 
be exposed to a range of doses of erythromycin which is an AcrAB-TolC 
substrate, and to temperatures of 30oC and 37oC. These temperatures fall in the 
thriving range of E. coli and many other human pathogens. 
 
In this particular study, resistance will be defined in a scalar manner as an 
increase in the MIC in comparison to the wild-type MIC (or any other reference 
MIC), a concept that is widely used in the field that built the foundation of strict 
clinical definitions of resistance with defined breakpoints  [117, 118, 119, 120].  
 
In order to look into the effect of temperature on resistance provided by AcrAB-
TolC, the following list of objectives will be met: 
1) Confirm that temperature does affect growth rate by obtaining growth 
curves at 30oC and 37oC for each strain 
2) Obtain OD-to-CFU/ mL conversion factors for both temperatures and all 
strains to decide on a standard inoculum size for MIC experiments 
3) For MIC experiments, expose bacteria to different erythromycin doses for 
24 hours at both temperatures, record MICs and observe any MIC shifts. 
Are faster growing cells more or less sensitive to erythromycin? 
4) If MIC shifts do occur, calculate and compare AcrB expression per cell 
between temperatures 
It should be noted that due to the focus on bacterial growth, this research will 
generate kinetic data only. 
 
By achieving the above objectives, the effect of temperature on AcrAB-TolC-
mediated resistance in E. coli can be elucidated, which will provide a general 
preliminary insight into the effect of temperature on antibiotic resistance. This 
project may provide a stepping stone into further investigation on the influence 
of temperature on other resistance mechanisms deployed by different 
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pathogens, as well as looking into the efficacy of several classes of antibiotics in 
cooler and warmer conditions. Together, it is hoped that this information will 
help guide treatment behaviours in different climates across the globe as well 
as in different parts of the body to be more effective whilst reducing the impact 































Chapter 2 – Obtaining OD-to-CFU/ mL Conversion Factors and 
Investigating the Effect of Temperature on the Growth Profiles of E. coli 
Strains MG1655, eTB108 and AG100-A 
  




In order to investigate the effect of temperature on antibiotic resistance, 
particularly that of which is provided by AcrAB-TolC, derivatives of the natural 
host of the efflux pump and model organism E. coli strain K-12 were used 
(Table 2.1).  
Wild-type (WT) E. coli MG1655 will be compared to experimental strain eTB108 
(‘evolved TB108’), the latter which expresses a modified AcrAB-TolC where the 
acrB gene is physically-fused to superfolder green fluorescent protein gene 
(sfGFP) downstream [68, 121]. When expressed, fluorescence is emitted under 
light of a wavelength of 485nm, allowing the measurement of AcrAB-TolC 
abundance through fluorescence intensity (FI). Its predecessor strain TB108 
was provided by Dr Tobias Bergmiller at the University of Exeter, however due 
to subnormal AcrAB-TolC efflux quantified by a lower MIC than another wild-
type E. coli strain AG100 (also another K-12 derivative), TB108 was evolved by 
Dr Carlos Reding-Roman in order to regain wild-type efflux functionality. The 
MIC of eTB108 was shown to be indistinguishable from the MIC of AG100 [68]. 
 
In order to confirm the role of AcrAB-TolC in antibiotic resistance, the acrAB 
knockout strain AG100-A will be used for comparison.   
 
Table 2.1: Escherichia coli K-12 derivative strains used in this study. 
Strain Genotype Reference 
E. coli AG100-A argE3 thi-3 rpsL xyl mtl 
supE44 ∆acrAB::Tn903 
122 
E. coli MG1655 ilvG-rfb-50 rph-1 122 








All media listed were created using deionised water up to a volume of 1 litre, 
where the final mixture was sterilised by autoclaving for 20 minutes at 121oC. 
 
 
Media (1L) Component(s) Supplier 
LB Agar 25g         LB Powder 




(20 mL component A + 
20 mL component B) 
Component A (1L): 
350g       K2HPO4 
100g       KH2PO4 
 
Component B (1L): 
29.4g      Trisodium Citrate 
50g         (NH4)2SO4 











When required, M9 (minimal) media was prepared fresh by supplementing M9 
salts (Table 2.2) with 0.2% (weight/volume) glucose and 0.1% (w/v) casamino 
acids. Stock solutions of glucose and casamino acids were created using M9 
salts as the liquid component (Table 2.3), where the final solution was filter-








Stock Solution (200mL) Components Supplier 
20% Glucose 40g Glucose Sigma Aldrich 
10% Casamino acids 20g casamino acids Formedium 
Table 2.2: Recipes for all media used throughout study. 
Table 2.3: Stock solutions used to create M9 media. 
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2.1.3 Growth Curve Protocol 
 
In order to investigate the effect of temperature on the growth of the strains of 
E. coli, a pure culture for each strain was created by streak-plating a loopful of 
frozen stock onto LB agar. The plate was then placed into a 30oC incubator for 
18 hours overnight. After, a single colony was picked and inoculated into 25 mL 
of M9 media, where the resultant mixture was placed in a shaking incubator at 
30oC at 180 rpm for 18 hours. 
 
The overnight culture was then successively diluted 1:1000 in M9 media in 3 
different conical flasks (for a biological triplicate), after which the optical density 
(OD) was immediately read and recorded 3 times per flask (for a technical 
triplicate) using a digital colorimeter (Fisher Scientific) (Fig. 2.1A). Thereafter, 
the flasks were placed in a shaking incubator at 180 rpm set at the experimental 
temperature of either 30oC or 37oC, where the OD was read in the 
aforementioned manner hourly up to 31 hours. 
 
2.1.4 Obtaining OD-to-CFU/ mL Conversion Equations 
 
Simultaneously, the colony forming unit per mL (CFU/ mL) for the 6th, 8th, 24th, 
26th, 28th and 30th hour was measured to obtain an average OD-to-CFU 
conversion equation for each strain at each temperature. This would enable a 
standard inoculum size to be used for subsequent experiments. After recording 
the OD at the hours mentioned above, a small sample was taken from each 
culture flask for a 2-fold serial dilution, resulting in a total of 5 dilutions plus the 
original undiluted sample. A microplate was used to hold the large number of 
dilutions for all three biological samples (Fig. 2.1B).  
After the OD was read for each 2-fold dilution, the next step was to create a 
series of further 10-fold dilutions on the same microplate, of which the number 
of viable cells per mL would be countable when a 10 µL drop was plated onto 
LB agar i.e. between 30 to 300 colonies. The dilutions were 10-2, 10-4, 10-5, 10-6 
and 10-7, but only four were drop-plated at a time depending on the turbidity of 
the culture i.e. for the 6th and 8th hour, dilutions 10-2, 10-4, 10-5 and 10-6 were 
plated, whereas for the 24th, 26th, 28th and 30th hour, 10-4, 10-5, 10-6 and 10-7 
were plated due to a higher bacterial density as a result of longer growth time. 
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Each LB plate used was split in half, where one side contained three 10 µL 
drops (technical triplicate) of one dilution e.g. 10-2 and the other side another 
dilution e.g. 10-4. 
Once dried, the plates were then placed in an incubator overnight at 30oC to 
allow colonies to grow. One dilution with countable colonies per 2-fold dilution 
(including the undiluted sample) was then picked and enumerated, and the 
CFU/ mL calculated using the following equation: 
 
CFU/ mL = number of colonies x dilution factor 
              volume of culture plated 
 
The CFU/ mL was then plotted against the recorded OD for all 2-fold dilutions 
and undiluted samples to obtain a regression of that time point, and the 
equation of the line averaged out over all 6 time points to obtain one equation. 
As mentioned previously, this mean function will act as the OD-to-CFU/ mL 
conversion equation for that strain and particular temperature, as it averages 
out potential variations in the relationship between OD and CFU/ mL that may 
occur over the whole growth cycle of the E. coli strain e.g. changes in cell size 
[123], where larger cells may give the same CFU/ mL measurement but a 
higher OD read. 
 
Please note that due to the measurements being manual, the OD was not read 
nor the culture plated for colony counts between the hours of 9 and 23, during 




































Single colony of 
MG1655/ eTB108/ 
AG100-A grown in 25 
mL of M9 minimal 
media for 18 hours at 
30oC at 180 rpm 
Overnight 
culture diluted 
1:1000 in fresh 
M9 minimal 







Figure 2.1A: A schematic of the general growth curve protocol used in this study for each 
strain and experimental temperature. 
Place in shaking 
incubator at experimental 
temperature (30oC or 
37oC) at 180 rpm 
Every hour 
(except 9 – 23) 
Measure 
CFU/ mL 


















Figure 2.1B: A schematic of the protocol used to measure OD and CFU/ mL of a series of 
2-fold dilutions for the 6th, 8th, 24th, 26th, 28th and 30th hour of culture growth. The green 
rectangle represents an example set of dilutions that may be plated for CFU counting. OD 
vs CFU/ mL graph will enable deduction of an OD-to-CFU/ mL conversion equation for each 
strain and temperature. 
Step 1: Five 2-fold 
dilutions created from 
each flask and all OD 
measured  
Step 2: Four to five 10-
fold dilutions created 
for each 2-fold dilution 





at 6th, 8th, 24th, 
26th, 28th and 30th 
hour (see Fig. 
2.1A) 
Drop-plates of 10-fold 
dilutions made, per 2-
fold dilution and 





All LB plates placed 
in 30oC incubator 
overnight, after 
which colonies 
counted from one 
10-fold dilution for 






2.2.1 A Comparison of Growth Curves between Strains 
 
The OD data obtained from the growth curve protocol for each strain were 
plotted against time and compared.  
At 30oC (Fig. 2.2), WT strain MG1655’s lag phase occurs between hours 0 – 4, 
progresses through to exponential phase where it eventually approaches a 
potential stationary phase at (or possibly before) 24 hours, reaching an average 
carrying capacity of 2.8 ± 0.036 OD. It can also be seen that eTB108 follows a 
similar pattern over time, however using an unpaired t-test confirmed that the  
mean OD reads for eTB108 was statistically higher than those of MG1655 (p < 
0.05) throughout most of the time points. However, statistical differences do not 



































24 26 28 30 32
Figure 2.2: Growth curves over time for E. coli strains MG1655 (WT, blue), eTB108 
(acrB-sfGFP, orange) and AG100-A (∆acrAB, grey) at 30oC. Overnight culture of 
each strain diluted 1:1000 in M9 media and allowed to incubate up to 31 hours. OD 
read hourly (except between 9 - 23 hours). Data points include biological and 
technical triplicate, where error bars represent standard error of the mean. Error bars 
may be small and hidden behind data points. Asterisk (*) placed above data points 
indicates a statistically-significant difference of eTB108 (orange) or AG100-A (grey) 
from the WT growth profile, where p < 0.05 using an unpaired t-test (see Table S1 in 
supplementary for exact p-values). 
 *     *     *    *     *     *     *     * 
*     *     *     *     *     *    * 
*   *   
*          *     *     *     *     * 
*     *     *           *     * 
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and 26th hour, the mean OD of MG1655 and eTB108 are statistically similar. 
Nonetheless, eTB108 reaches an average carrying capacity of 3 ± 0.041 OD, 
which is statistically higher than that of MG1655 (p = 0.0019). 
The acrAB-knockout strain AG100-A grew to a significantly lower carrying 
capacity in contrast to the other two strains. In fact, the final average OD 
measured was at least 5-fold less than that of the others (0.5 ± 0.00031 OD).  
At 37oC (Fig. 2.3), similar to the results obtained at 30oC (Fig. 2.2), some OD 
measurements in the latter half of growth are significantly different between 
MG1655 and eTB108 (25th, 27th, 28th, 29th and 31st hour), whilst others are not 
(24th, 26th and 30th hour). However, unlike 30oC, MG1655 reaches a statistically 
higher average carrying capacity of 2.49 ± 0.045 OD (p = 0.0409), whilst 
eTB108 plateaus at 2.37 ± 0.032 OD. Furthermore, the mean carrying capacity 
of AG100-A is again significantly lower than that of MG1655, at approximately 



































24 26 28 30 32
Figure 2.3: Growth curves over time for E. coli strains MG1655 (WT, blue), eTB108 
(acrB-sfGFP, orange) and AG100-A (∆acrAB, grey) at 37oC. Overnight culture of each 
strain diluted 1:1000 in M9 media and allowed to incubate up to 31 hours. OD read 
hourly (except between 9 - 23 hours). Data points include biological and technical 
triplicate, where error bars represent standard error of the mean. Error bars may be 
small and hidden behind data points. Asterisk (*) placed above data points indicates a 
statistically-significant difference of eTB108 (orange) or AG100-A (grey) from the WT 
growth profile, where p < 0.05 using an unpaired t-test (see Table S2 in supplementary 
for exact p-values). 
 *      *     *     *    *     *   
*     *     *     *     *     *     *     * *     *     *    *     * 
*   *   
*           *     *     *           * 
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2.2.2 A Comparison of Growth Curves between Temperatures 
 
The OD data was then plotted separately for each strain to see how an increase 




When the temperature is increased from 30oC to 37oC, the earliest part of 
division i.e. 3 to 8 hours is observed to be significantly quicker for MG1655 (Fig. 
2.4). This may suggest that the cells are dividing much more quickly at 37oC, 
however more data points will be required to calculate and compare growth 
rates since with the current data the exponential phase cannot be visualised. In 
addition, the overall OD recorded at the potential stationary phase (24 – 31 
hours) is statistically higher at 30oC (2.8 ± 0.036 OD) than at 37oC (2.49 ± 0.045 
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Figure 2.4: Growth curves over time for E. coli strain MG1655 (WT) at 30oC (blue) 
and 37oC (red). Overnight culture of strain diluted 1:1000 in M9 media and allowed 
to incubate up to 31 hours. OD read hourly (except between 9 - 23 hours). Data 
points include biological and technical triplicate, where error bars represent 
standard error of the mean. Error bars may be small and hidden behind data 
points. Asterisk (*) placed above data points indicates a statistically-significant 
difference in OD between temperatures, where p < 0.05 using an unpaired t-test 
(see Table S3 in supplementary for exact p-values). 
*                 *     *     *     *     *     * 





With regards to the potential difference in growth rates, the same applies to 
eTB108 (Fig. 2.5) where it may be significantly higher in 37oC but difficult to 
firmly determine without further data points. The carrying capacities on the other 
hand are again statistically different (p < 0.0001), where the average final OD 
obtained at 30oC is significantly higher (3 ± 0.041 OD) than that obtained at 










Figure 2.5: Growth curves over time for E. coli strain eTB108 (acrB-sfGFP) at 30oC (blue) 
and 37oC (red). Overnight culture of strain diluted 1:1000 in M9 media and allowed to 
incubate up to 31 hours. OD read hourly (except between 9 - 23 hours). Data points include 
biological and technical triplicate, where error bars represent standard error of the mean. 
Error bars may be small and hidden behind data points. Asterisk (*) placed above data 
points indicates a statistically-significant difference in OD between temperatures, where p < 



































 *    *     *     *     *     *     * 
 *     *     *     *     *     *     *     * 





In contrast, from the OD data obtained for AG100-A at both temperatures (Fig 
2.6), the mean carrying capacity is significantly higher at 37oC (0.75 ± 0.005 
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Figure 2.6: Growth curves over time for E. coli strain AG100-A (∆acrAB) at 30oC (blue) and 
37oC (red). Overnight culture of strain diluted 1:1000 in M9 media and allowed to incubate up 
to 31 hours. OD read hourly (except between 9 - 23 hours). Data points include biological 
and technical triplicate, where error bars represent standard error of the mean. Error bars 
may be small and hidden behind data points. Asterisk (*) placed above data points indicates 
a statistically-significant difference in OD between temperatures, where p < 0.05 using an 
unpaired t-test (see Table S5 in supplementary for exact p-values). 
*     *     *     *    *     *     *     * 
*     *     * 
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2.2.3 OD-to-CFU/ mL Conversion 
 
2.2.3.1 Conversion Factor per Time Point 
 
As mentioned previously in section 2.1.4, for the hours 6, 8, 24, 26, 28 and 30, 
OD was plotted against CFU/ mL to obtain regressions in the form of CFU/ mL = 
OD x CF, where CF represents the OD-to-CFU/ mL conversion factor (see Fig. 
S1 - S6 and Table S10 in supplementary). The conversion factors were then 
plotted over time for each strain and temperature below. Note that large 
numbers on the y-axis are in exponential notation (E + n), where E multiplies 






For MG1655 (Fig. 2.7), at most of the time points (with the exception of the 24th 
hour), there is a statistically significant difference in the OD-to-CFU/ mL 
conversion factor between the two temperatures, where there are more viable 
cells per OD in 37oC. 
Figure 2.7: OD-to-CFU/ mL conversion factor over time for E. coli strain MG1655 (WT) at 
30oC (blue) and 37oC (red). Overnight culture of strain diluted 1:1000 in M9 media and 
allowed to incubate up to 31 hours. For hours 6, 8, 24, 26, 28 and 30, OD and CFU/ mL 
recorded for half dilutions to obtain equation of line i.e. OD-to-CFU/ mL conversion factors. 
Data points include biological and technical triplicate, where error bars represent standard 
deviation of the regression slope. Error bars may be small and hidden behind data points. 
Asterisk (*) placed above data points indicates a statistically-significant difference between 
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Trends are not nearly as evident in eTB108 (Fig. 2.8) and AG100-A (Fig. 2.9), 
where between the temperatures the OD-to-CFU/ mL conversion factor is either 
statistically the same (for eTB108, hours 24, 26, 28 and AG100-A, hours 6 and 
8) significantly higher in 30oC and less in 37oC (for eTB108, the 30th hour and 
AG100-A, hours 26, 28 and 30) or vice versa (eTB108 hours 6 and 8).  
 
Nonetheless, for better comparison between strain and temperature as well as 
deciding on an appropriate inoculum size for the next set of experiments, the 
values for all time points were averaged out and plotted to give a mean 

















































Figure 2.8: OD-to-CFU/ mL conversion factor over time for E. coli strain eTB108 (acrB-
sfGFP) at 30oC (blue) and 37oC (red). Overnight culture of strain diluted 1:1000 in M9 media 
and allowed to incubate up to 31 hours. For hours 6, 8, 24, 26, 28 and 30, OD and CFU/ mL 
recorded for half dilutions to obtain equation of line i.e. OD-to-CFU/ mL conversion factors. 
Data points include biological and technical triplicate, where error bars represent standard 
deviation of the regression slope. Error bars may be small and hidden behind data points. 
Asterisk (*) placed above data points indicates a statistically-significant difference between 
temperatures, where p < 0.05 using an unpaired t-test (see Table S7 in supplementary for 
exact p-values). 



























































Figure 2.9: OD-to-CFU/ mL conversion factor over time for E. coli strain AG100-A (∆acrAB) 
at 30oC (blue) and 37oC (red). Overnight culture of strain diluted 1:1000 in M9 media and 
allowed to incubate up to 31 hours. For hours 6, 8, 26, 28 and 30, OD and CFU/ mL 
recorded for half dilutions to obtain equation of line i.e. OD-to-CFU/ mL conversion factors.  
Observations at 24 hours at 37oC have been omitted due to error. Data points include 
biological and technical triplicate, where error bars represent standard deviation of the 
regression slope. Error bars may be small and hidden behind data points. Asterisk (*) 
placed above data points indicates a statistically-significant difference between 
temperatures, where p < 0.05 using an unpaired t-test (see Table S8 in supplementary for 
exact p-values). 
 *     *     * * 
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2.2.3.2 Mean OD-to-CFU/ mL Conversion Factors and Standardising the 
Inoculum Size 
 
Apart from MG1655, the average OD-to-CFU/ mL conversion factor does not 
change with increasing temperature for the other strains (Fig. 2.10). There is 
approximately a 1.8-fold increase for MG1655 when increasing the temperature 
to 37oC. It should also be noted that, relative to the mean value reported at 
30oC for MG1655, both values for eTB108 are statistically similar, whereas both 
conversion rates for AG100-A are ~5-fold less. The mean values in Table 2.4 
were used to standardise the inoculum size for subsequent experiments and to 














































Figure 2.10: Average OD-to-CFU/ mL conversion factor for E. coli strains MG1655 (WT), 
eTB108 (acrB-sfGFP) and AG100-A (∆acrAB) at 30oC (blue) and 37oC (red). Overnight 
culture of strain diluted 1:1000 in M9 media and allowed to incubate up to 31 hours. For 
hours 6, 8, 24, 26, 28 and 30, OD and CFU/ mL recorded for half dilutions to obtain 
equation of line i.e. OD-to-CFU/ mL conversion factors. Factors averaged out over time 
points to give mean conversion factor per temperature per strain. Data points include 
biological and technical triplicate, where error bars represent standard error of the mean. 
Statistical significance between two values where p < 0.05 using an unpaired t-test is 





Note: see Fig. S1 – S6 and Table S10 in supplementary for individual conversion factors 
per time point, prior to averaging, and their corresponding R2 values 
 
For simplicity, the chosen inoculum size for the next set of experiments in 
chapter 3 was 2.03 x 109 cells per mL, as this is the same number that MG1655 
reaches when grown at 30oC for approximately 18 hours of culture time (~1.4 
OD). Therefore, this will require the overnight culture for the experiments to 

















E. coli Strain OD-CFU/ mL Conversion Factor 
 
30oC 
Mean ± SEM 
(x 108) 
37oC 
Mean ± SEM 
(x 108) 
MG1655 (WT) 14.5 ± 2.3 26.7 ± 3 
eTB108 (acrB-sfGFP) 15.7 ± 2.5 16.7 ± 1.9 
AG100-A (∆acrAB) 3 ± 0.9 2.7 ± 1.6 






The primary aim of this chapter was to obtain growth curves, CFUs during 
growth, and ultimately OD-to-CFU/ mL conversion factors for E. coli strains 
MG1655, eTB108 and AG100-A at both 30oC and 37oC. This would help 
standardise the inoculum size for the next set of experiments in chapter 3, and 
was achieved by allowing each strain to grow in M9 media up to 31 hours, 
during which their OD was recorded and intermittently their CFU/ mL also. 
 
During these calibration experiments, the aim was also to confirm the 
assumption of similarities (and if not, highlight the differences) between WT 
strain MG1655 and sfGFP-tagged eTB108, since the presence of sfGFP in the 
genome of eTB108 has been shown to not affect the efflux function of AcrAB-
TolC [68].  
With regards to the growth curves obtained at 30oC and 37oC (Fig. 2.2 and Fig 
2.3 respectively), surprisingly eTB108 and MG1655 overall differ from one 
another statistically between 24 – 31 hours. In particular, at 30oC, eTB108 has a 
significantly higher average carrying capacity than MG1655. Initially, it could be 
assumed that the presence of sfGFP has somehow affected metabolism of the 
cell, however, if anything, the likelihood is that the presence of sfGFP may have 
an energy cost associated with it, albeit large or small [124]. This would imply 
that MG1655 should have a higher carrying capacity as it is able to utilise more 
energy for growth, but this is not the case at 30oC.  Specifically for standard 
GFP, its presence has been shown to have no significant effect on the 
physiology or the growth of bacteria and other organisms including E. coli [125, 
126].  The main difference between GFP and sfGFP is that sfGFP has improved 
folding efficiency providing enhanced fluorescence, as well as being more 
stable at elevated temperatures [127]. Furthermore, at 37oC, the opposite is 
seen where MG1655 has a higher average carrying capacity than sfGFP-
tagged eTB108, further confirming that sfGFP is most likely not affecting 
growth. Another possibility as to why eTB108 has a greater carrying capacity at 
30oC in comparison to MG1655 may be due to how the strain itself was 
developed. As mentioned in section 2.1.1, TB108 was evolved to regain wild-
type efflux activity, which led to eTB108. Specifically, this was done by growing 
TB108 at 30oC via batch culture transfer into new media per day, over a total of 
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7 days. The bacteria were also exposed to a low basal concentration of 
erythromycin in order to select for populations with comparatively higher levels 
of efflux function [68]. During this process however, the strain may have evolved 
adaptive mutations that increase its fitness at 30oC, allowing more efficient 
growth at this temperature and thus leading to higher yield. To test this, an 
acrAB knockout strain, such as AG100-A, may be grown in the same conditions 
as the aforementioned evolutionary experiment. The presence of adaptive 
mutations may be indicated by the increase in fitness over the duration of the 
experiment i.e. an overall increase in carrying capacity. 
 
In the case of the growth curves of AG100-A obtained at both temperatures (Fig 
2.2, Fig 2.3 and Fig. 2.6), bacterial proliferation is considerably more stunted 
leading to relatively much lower carrying capacities. This may be expected, 
since AcrAB is postulated to be involved in the efflux of metabolic waste from 
processes such as enterobactin, cysteine and purine biosynthesis as well as 
gluconeogenesis [128]. The up-regulation of AcrAB expression has been shown 
to occur from the increased expression of acrAB operon regulators SoxS and 
MarA as a result of metabolite accumulation [128, 129]. Therefore the absence 
of AcrAB in AG100-A is likely to have led to the accumulation of metabolites 
within the bacterial cells, leading to potential DNA damage and protein 
denaturation [129, 130]. Due to the toxic effect of poor pump function, efflux 
pump inhibitors are being looked into as potential therapeutic agents in the 
clinic [131, 132, 133].  
In addition, AG100-A harbours the mutation argE3, preventing arginine 
biosynthesis. Arginine is required for the synthesis of proteins and nitrogen-
containing compounds in E. coli and other bacteria, and therefore its absence is 
likely to affect cell growth [134, 135, 136]. This, in combination with impaired 
efflux activity, are likely contributing to the lower yield observed in the above 
experiments. 
 
The next step was to do a side-by-side comparison to see the effect of 
temperature on the growth profiles of each strain. With the exception of AG100-
A (Fig. 2.6), both MG1655 (Fig. 2.4) and eTB108 (Fig 2.5) show a higher 
average carrying capacity at 30oC than at 37oC. This could potentially be due to 
a growth rate-yield trade-off i.e. the incompatibility of high biomass generation 
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per time with high biomass generated per mole of glucose, postulated to be as 
a result of thermodynamic constraints [137]. In other words, slow-growing 
bacterial cells are, overall, able to produce more offspring from one mole of 
glucose (or any other carbon source) than their faster-growing counterparts. 
This phenomenon is theorised to occur in natural environments as a result of 
competition for resources [137]. A growth rate-yield trade-off has been 
demonstrated empirically in E. coli, where the growth rate was manipulated by 
adapting the bacteria to the environment through serial passage [138].  
Although higher cell numbers can be seen in Fig. 2.4 and Fig. 2.5 at 30oC in 
comparison to 37oC, coupled with the knowledge that E. coli cells grow faster 
(and at their optimal) at 37oC [100], a growth rate-yield trade-off (and a lack 
thereof in AG100-A, Fig 2.6) can only be speculated due to no calculated 
growth rates.  
Growth rates could not be obtained since the exponential phase could not be 
visualised as a result of the absence of OD data between 9 – 23 hours. 
However, using an automated plate reader by which OD will be read every 20 
minutes for a span of 24 hours, an attempt at investigating the effect of 
temperature on growth rate will be made in the next chapter.  
 
It should be noted that slower-growing cells (specifically where their proliferation 
rate has been manipulated by nutrient levels) have been shown to be more 
tolerant to changing conditions such as sudden antibiotic exposure [102, 103, 
105]. By obtaining growth rates, the next chapter will also attempt to elucidate 
whether this relationship between growth rate (specifically manipulated by 
temperature) and antibiotic susceptibility applies to E. coli and its response to 
erythromycin. 
 
Finally, the main aim of this chapter was accomplished by obtaining the OD-to-
CFU/ mL conversion factors for all three strains at 30oC and 37oC (Fig. 2.10 and 
Table 2.4). The relationship between OD and CFU/ mL were statistically the 
same for eTB108 and MG1655 at 30oC, further confirming their similarities 
suggesting that the expression of sfGFP, at the levels involved in this study, 
may not impact cell growth. Apart from eTB108 and AG100-A where the effect 
of temperature is negligible, MG1655 is the only strain to have a significantly 
higher (~2-fold increase) conversion factor at 37oC. In other words, per unit of 
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OD, there are almost double the number of viable cells. Why this occurs only in 
MG1655 and not in eTB108 may be difficult to explain without visualising the 
dynamics of OD and CFU/ mL over time, and any physiological changes that 
the bacteria may undergo as a result of temperature. It could be speculated that 
at 37oC, the size of bacterial cells are smaller, and assuming that they have 
lower energetic costs than one large cell, exist in almost twice the amount per 
mole of glucose in comparison to 30oC. An increase in temperature has been 
shown to reduce cell size in E. coli in past studies [139, 140]. However, again if 
this were the case, why is the same relationship between OD and CFU/ mL not 
observed in eTB108 when increasing the temperature from 30oC to 37oC? As 
well as comparing CFU/ mL dynamics with OD, the theory that MG1655 cells 
may become smaller at higher temperature can be tested via single-cell 
microfluidics [141], where changes in cell size can be physically observed in 
real-time whilst manipulating the temperature. 
  
Nonetheless, as mentioned previously, these OD-to-CFU/ mL conversion 
factors will serve their purpose in the following chapter. 
 
A limitation of this study is that the OD measurements taken by the 
spectrophotometer may be close or even below the detection threshold of the 
equipment, particularly in the earlier hours of bacterial growth. Furthermore, 
hourly conversion factors were derived for limited time points (6th, 8th, 24th, 26th, 
28th and 30th) and averaged for comparability between strains and temperature, 
which may not be representative of the whole growth curve nor of the specific 
OD-to-CFU/ mL relationship for each time point/ growth phase. This may lead to 
potential underestimation/ overestimation of the CFU/ mL dependent on the 
total duration of cell growth. If the experiments described in sections 2.1.3 and 
2.1.4 were to be repeated, a more accurate method would be to feasibly 
determine conversion factors at regular intervals throughout the whole growth 
cycle (within all growth phases), and for each strain/ temperature choosing one 
time point confidently within stationary phase to determine the inoculum size. 
This will enable the inoculum size to be more easily achieved by growing the 
strains for a predetermined amount of time under the standard conditions and 
specific temperature, with the cells at the same growth stage, minimising 
variability between experiments. 
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Chapter 3 – The Effect of Temperature on the MIC of MG1655, eTB108 and 
AG100-A, and on the Selection of Pump Expression 
 
The overall aim of this chapter is to investigate the effect of a temperature 
increase on the susceptibility of E. coli to erythromycin and ultimately, changes 
in the expression of AcrB in order to understand the selection on pump 
expression under thermal variation. 
 
3.1 Materials and Methods 
 
The E. coli strains described in section 2.1.1 and M9 media described in section 
2.1.2 will be used throughout the following experiments in this chapter. 
 
3.1.1 Erythromycin Stock 
 
10 mg/ mL stock solutions of erythromycin were made by dissolving 100 mg of 
erythromycin powder, provided by Abcam Ltd. (AB141205), into 10mL of pure 
ethanol and then aliquoted into 1mL eppendorf tubes. All aliquots were 
maintained in -20oC for no longer than 1 month as per product instructions. 
 
3.1.2 Plate Reader Setup 
 
To be able to see the effects of temperature on the MIC of each strain, and 
AcrB expression in eTB108, the FLUOstar OPTIMA plate reader was used 
which is capable of measuring OD and FI simultaneously. 
 
Upon start up, the plate reader was set up to heat and maintain the 
experimental temperature (30oC or 37oC). A script was curated for the plate 
reader to follow, which involved OD and FI readings of each well every 20 
minutes for a total duration of ~24 hours. Specifically, this consisted of 
approximately 5 minutes of shaking time at medium strength, and 15 minutes of 
OD and FI measurement three times per well in a 2x2 matrix. OD was read 
using the 600nm filter and sfGFP FI was read using the excitation/ emission 




3.1.3 MIC Assay 
 
As the MIC can vary for different experiments based on strain, media and many 
other factors, this study will involve obtaining MICs specific to the experimental 
strains and media used in this research project. 
 
In order to obtain an MIC for each strain and temperature, a single colony was 
picked from a streak plate and inoculated into 25 mL of M9 minimal media. The 
mixture was then placed into a shaking incubator at 30oC at 180 rpm for 18 
hours. After, the overnight culture was then used to create three more overnight 
cultures by making three 1:1000 dilutions and incubating in a similar manner to 
the above for a biological triplicate.  
 
The aim was for the second set of cultures to reach a cell number of 2.03 x 109 
per mL based on the deduced OD-to-CFU/ mL conversion factors (Table 2.4), 
which would require an OD of 1.4 for MG1655 and 1.3 for eTB108, easily 
achieved after 18 hours of incubation. However, as AG100-A required an 
overnight culture of 6.8 OD, a much higher OD that surpasses the carrying 
capacity of ~0.5 OD recorded in Fig. 2.2, the second set of AG100-A overnight 
cultures were made to be significantly larger in volume. From these larger 
cultures, a sample was taken and exposed to a cycle of centrifugation and 
resuspension with more culture until the desired OD was achieved, a standard 
microbiological procedure to concentrate bacteria in a sample [142, 143, 144, 
145, 146]. 
 
After, for each strain, the three overnight cultures (now experimental samples) 
were transferred onto a microplate in the manner shown in Fig. 3.1, where three 
columns were dedicated to each sample and each well contained 150 µl of said 
sample. Columns 10, 11 and 12 remained empty to prevent inoculation of E. 
coli cells into the blank (explained further below). A sterile 96-pin replicator 
(Boekel Scientific, US), was then used to transfer 1% of each well onto a 
microplate that contained wells of 150 µl of M9 media supplemented with 
erythromycin to create a concentration gradient ranging from 0 - 70 µg/ mL 
down each of the rows. This approximated to 3.04 x 106 cells being introduced 
into the new wells for each strain.  Due to the empty columns on the previous 
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plate, the final three columns of the new plate contained M9 media only without 
any cells as a blank. The freshly inoculated microplate was then placed into the 
plate reader at either 30oC or 37oC in which the OD and FI were recorded every 

















Sample 1 Sample 2 Sample 3 
Figure 3.1: The overall protocol used to inoculate microplates with E. coli strains MG1655, eTB108 or AG100-A to determine MICs and measure FI using plate 
reader. 
M9 Only 
1:1000th dilution of 
overnight culture to 
make 3 more 
cultures of required 
OD i.e. biological 
triplicate. Once 
again, inoculated 
vials placed in 30oC 
shaking incubator at 
180 rpm overnight. 
Place into plate reader at 
30oC/ 37oC to read optical 
density and fluorescence 
intensity every 20 minutes 
up to 24 hours. 
150 µL of sample 
(containing 2.03 x 109 
cells per mL) placed 
in each well. Column 
10-12 left empty. 
1% of each well 
(~3.04 x 106 
cells) inoculated 




fresh M9 media. 
Rows 10-12 not 
inoculated to 
serve as blank. 
Overnight culture grown in 30oC 
in shaking incubator at 180 rpm 





Due to the intermittent reading of OD every 20 minutes over the span of 24 
hours using the plate reader, the data provided by the wells that were not 
exposed to erythromycin (A1 – A9, Fig. 3.1) were exploited to visualise the 
growth cycle for each strain at 30oC and 37oC  (Fig. 3.2 – 3.4).  
 
3.2.1 Growth Rate Increases with Temperature 
For MG1655 (Fig. 3.2), the bacteria proliferate between ~620 – 840 minutes 
(10.3 – 14 hours) at 30oC, and at 37oC between ~360 – 480 minutes (6 – 8 
hours).  
For eTB108 (Fig. 3.3), population growth occurs between ~520 – 860 minutes 
(8.7 – 14.3 hours) at 30oC, and at 37oC between ~240 – 460 minutes (4 – 7.7 
hours). 
With regards to AG100-A (Fig. 3.4), at 30oC it is much more difficult to pinpoint 
the time frame in which proliferation occurs due to large standard-error-of-the-
mean values. At 37oC, however, the phase occurs between ~340 – 460 minutes 





































Figure 3.2: Growth curves over time for E. coli strain MG1655 (WT) at 30oC (blue) 
and 37oC (red) using plate reader. OD read every 20 minutes up to 1440 minutes 
(24 hours). Data points include biological and technical triplicate, where error bars 









































Figure 3.3: Growth curves over time for E. coli strain eTB108 (acrB-sfGFP) at 30oC (blue) 
and 37oC (red) using plate reader. OD read every 20 minutes up to 1440 minutes (24 hours). 
Data points include biological and technical triplicate, where error bars represent standard 
error of the mean. Error bars may be small and hidden behind data points. 
Figure 3.4: Growth curves over time for E. coli strain AG100-A (∆acrAB) at 30oC (blue) and 
37oC (red) using plate reader. OD read every 20 minutes up to 1440 minutes (24 hours). 
Data points include biological and technical triplicate, where error bars represent standard 







































Please note that the final ODs measured by the plate reader (Fig. 3.2 – 3.4) are 
not the same as those measured by the colorimeter (Fig. 2.2 – 2.6), likely due to 
factors such as use of different machinery and thus the culture environment.  
 
In fact, from the plate reader measurements, it can be seen that the carrying 
capacity is not reached for all three strains due to continuous proliferation (Fig 
3.2 – 3.4). It is possible that diauxic growth is occurring, where there are visibly 
two cycles of growth that occur one after another [147]. Therefore potential 
growth rate-yield trade-offs cannot be observed with the current set of data. 
 
Mean growth rates for all strains and temperatures were obtained from the first 
growth phase (within the time frames mentioned above) using the GrowthRates 
programme, which calculated the growth rate for wells A1 – A9 by converting 
the OD data into natural logarithms (ln OD) and using the range of points where 
the greatest slope occurs i.e. within the exponential phase [148].  All 9 growth 
rates from each well were then averaged and plotted (Fig. 3.5) to compare 































Figure 3.5: Mean growth rate per minute for E. coli strains MG1655 (WT), eTB108 (acrB-
sfGFP) and AG100-A (∆acrAB) at 30oC (blue) and 37oC (red). Growth rates were 
calculated from exponential phase using GrowthRates programme [148].Data points 
include biological and technical triplicate, where error bars represent standard error of the 
mean. Statistical significance between two values where p < 0.05 using an unpaired t-test 





For all three strains (Fig. 3.5), it can be confirmed statistically that the growth 
rate is significantly higher at 37oC than at 30oC i.e. the E. coli strains grow more 
quickly at the higher temperature. 
 
3.2.2 MIC Increases with Temperature 
 
To investigate the effect of temperature on E. coli susceptibility to erythromycin, 
it was important to first establish the MIC of each strain at 30oC as reference. 
 
  
At 30oC, according to Fig. 3.6, the point at which there is no visible growth i.e. 
the MIC occurs for both MG1655 and eTB108 between 20 – 30 µg/ mL. In 
contrast, acrAB-knockout strain AG100-A appears to be relatively more 




Figure 3.6: Dose-response curves for E. coli strains MG1655 (WT, blue) and eTB108 (acrB-
sfGFP, orange) at 30oC (circle) and 37oC (triangle). Wells of microplate containing 
erythromycin gradient and fresh M9 media inoculated with 3.04 x 106 bacterial cells of 
MG1655 or eTB108. Inoculated plate then placed into plate reader at 30oC/ 37oC to read OD 
over 24 hours. Data points are average optical densities at the 24th hour and represent 
biological and technical triplicate, where error bars represent standard error of the mean. 

































Erythromycin Dose (µg/ mL)
MG1655 + eTB108 Dose-Responses





With regards to temperature and its effect on the MIC, it appears that in both 
MG1655 and eTB108, there is a positive shift with increasing temperature (Fig. 
3.6). 
 
For MG1655, the MIC increases from 20 – 30 µg/ mL of erythromycin to 30 – 40 
µg/ mL with increasing temperature. 
 
The same trend of increase is seen in eTB108, however this time the shift 
occurs from an MIC of 20 – 30 µg/ mL at 30oC to 40 – 50 µg/ mL at 37oC – 
potentially a 2-fold increase from that of which is seen in MG1655. 
 
However, with regards to AG100-A (Fig. 3.7), the effect of temperature on the 
MIC is inconclusive due to the level of noise at 37oC. From the initial part of the 
graph, it may be possible to predict no effect from temperature on MIC, however 




































Erythromycin Dose (µg/ mL)
AG100-A Dose-Response
30°C 37°C
Figure 3.7: Dose-response curves for E. coli strain AG100-A (∆acrAB) at 30oC (blue) and 
37oC (red). Wells of microplate containing erythromycin gradient and fresh M9 media 
inoculated with 3.04 x 106 bacterial cells. Inoculated plate then placed into plate reader at 
30oC/ 37oC to read OD over 24 hours. Data points are average optical densities at the 24th 
hour and represent biological and technical triplicate, where error bars represent standard 
error of the mean. Error bars may be small and hidden behind data points. 
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3.2.3 Selective Doses for Pump Expression Shift with Temperature 
 
Using the FI data at the 24th hour recorded by the plate reader for eTB108 at 
both temperatures, pump expression levels per cell were calculated by initially 
blank-correcting the FI per dose and then obtaining an average from the 
biological and technical repeats. At the same time, to find the number of cells 
per dose, the mean OD for each antibiotic concentration was then multiplied by 
the mean OD-to-CFU/ mL conversion rate for eTB108 (1.57 x 109 or 1.67 x 109 
depending on the temperature of the FI data). The mean FI was then divided by 
the number of cells to give FI per cell values for each dose. However, to see 
how expression levels may vary with dose and temperature relative to the 
normal basal expression of stationary-phase eTB108, all values were then 
divided further by the average FI per cell value of eTB108 at 30oC with no 






































Erythromycin Dose (µg/ mL)
30°C 37°C
Figure 3.8: Relative expression levels of AcrB per cell as a function of erythromycin dose of 
sfGFP-tagged E. coli strain eTB108 (acrB-sfGFP) at 30oC (blue) and 37oC (red) at the 24th 
hour. FI per cell values for both temperatures are averaged and relative to basal expression 
of acrB at 24th hour at 30oC with no drug. Wells of microplate containing erythromycin 
gradient and fresh M9 media inoculated with 3.04 x 106 bacterial cells. Inoculated plate then 
placed into plate reader at 30oC/ 37oC to read OD and FI over 24 hours. Data points 
represent average of biological and technical triplicate, where error bars represent standard 
error of the mean. Error bars may be small and hidden behind data points. Statistical 
significance using an unpaired t-test between two values where p < 0.05 is represented by 
asterisk(s) (*), and no statistical difference is denoted by ‘NS’ (NS: p = 0.9166, *: p = 0.0308, 







A visible difference can be seen in the peak of relative AcrB expression 
between the two experimental temperatures (Fig 3.8). At 30oC, the peak is at 10 
µg/ mL of erythromycin at a value of ~1.39. At 37oC, a statistically similar peak 
can be seen at the dose of 40 µg/ mL. Both peaks of pump expression occur 
below their corresponding temperature-specific MIC (20 – 30 µg/ mL at 30oC 
and 40 – 50 µg/ mL at 37oC, as seen in Fig 3.6). In other words, selection for 

























To reduce the rate at which antibiotic resistance is emerging, it is important to 
identify and study the factors that contribute to the rise, selection and fixation of 
resistance genes. Temperature, a potential selection pressure, has been 
recently shown to have a positive correlation with the percentage of bacteria, 
including E. coli, failing to respond to first-line antibiotics from a study that was 
conducted in the US [96]. However, how temperature selects for resistance 
mechanisms remains relatively underexplored. Understanding this cellular 
response is important, as ultimately treatments are designed and used to 
overcome these mechanisms specifically [20, 24, 25, 32, 131, 132, 133]. 
Although there are several mechanisms by which bacteria display resistance [7, 
17], the aim of this chapter was to observe any changes in the susceptibility of 
E. coli to erythromycin as a result of temperature increase, and subsequently 
the effect of temperature on the selection of expression of MDR-associated 
AcrAB-TolC. 
 
This was achieved by exposing all three strains of E. coli (MG1655, eTB108 
and AG100-A) to a range of doses of erythromycin over 24 hours of growth at 
30oC and 37oC. It was found that the erythromycin-associated MIC for both 
MG1655 and eTB108 increased as a result of increasing temperature (Fig. 3.6) 
and therefore the strains displayed a higher level of resistance at 37oC. In 
another study, an increase in resistance was also seen with E. coli and its 
response to rifampicin as a result of increasing temperature [108]. This was 
attributed to the selection and fixation of mutations within RNA polymerase, the 
target of rifampicin. Interestingly, in the aforementioned study, the E. coli cells 
were never exposed to rifampicin, concluding that the presence of the mutation 
provides an advantage at higher temperatures [108]. Another study showed that 
individual drugs respond differently based on the temperature that E. coli cells 
were adapted to [149]. Supporting the results in Fig. 3.6, the study found that 
erythromycin works synergistically with E. coli adapted to 30oC, i.e. a lower 
dose is required to inhibit bacterial growth, but antagonistically at 37oC. It was 
postulated (and shown experimentally for only the antibiotics tetracycline and 
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streptomycin) that antibiotics trigger HSPs and CSPs, similar to thermal stress 
[149]. This finding is valuable as it may help uncover similarities in the antibiotic 
and thermal response of pathogens, and by bridging this knowledge with how 
temperature selects for resistance mechanisms (such as drug efflux) can only 
further unshroud temperature-resistance relationships. 
It should be noted that there was a greater increase in the MIC for eTB108 
when shifting the temperature from 30oC to 37oC (Fig. 3.6), in comparison to 
MG1655. As mentioned in section 2.3, the evolution of TB108 to eTB108 via 
batch culture transfer may have allowed for adaptive mutations which increased 
the fitness of the strain. However, it may be speculated that other adaptive 
mutations have occurred, such as in other resistance (or resistance-regulatory) 
genes, which are expressed and generally more beneficial at 37oC (similar to 
RNA polymerase mutations and resistance to rifampicin as mentioned above 
[108]). The selection of such mutations may be in part due to the exposure of 
TB108 to a low concentration of erythromycin throughout the evolutionary 
experiment [80, 81]. As mentioned previously also in section 2.3, the 
development of non-efflux adaptations may be observed in real-time by 
exposing acrAB-knockout strain AG100-A to the conditions of the 
aforementioned evolutionary experiment - however this time the experiment to 
be conducted at 37oC. An increase in the carrying capacity over the duration of 
the experiment may indicate the presence of adaptive mutations. 
 
The next experiment of this chapter measured the expression of AcrB in 
eTB108 as a response to temperature increase, via the fluorescence emitted 
from the sfGFP tag physically-fused to the acrB gene. Firstly, it was found that 
expression of the pump was selected for at sub-inhibitory concentrations (Fig. 
3.8), which, in this discussion, will be termed as the AcrB-expression selection 
window. This is similar to results that have been observed in past studies, such 
as the selection of resistant mutants of Salmonella and E. coli with sub-MIC 
doses of other antibiotics [81], and even in the selection and maintenance of β-
lactamase plasmid-carrying E. coli and K. pneumoniae cells [150].  In Fig. 3.8, 
interestingly, there is a positive shift in the AcrB-expression selection window 
when increasing the temperature from 30oC to 37oC, however the window is still 
maintained at concentrations below the 37oC-specific MIC. Why such a shift 
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occurs as a result of temperature change is difficult to explain with the lack of 
research on conditions that may affect the position of selective windows. 
Nonetheless, the implication of this result, i.e. the resistance-selective 
concentrations for certain antibiotics may change as a result of temperature, 
may prove useful for deciding the dose of a drug when treating infections in 
different parts of the world to different parts of the body.  
 
An unexpected find is that in Fig. 3.8 erythromycin, a translation inhibitor, is 
allowing the expression of the protein AcrB. In theory, due to the limited “free” 
ribosomes in the presence of erythromycin, the bacterial cell should not be able 
to translate even the protein components of further ribosomes let alone a 
proteinaceous efflux pump. The significance of this finding is that a clinical drug 
with a specific mode of action is not carrying out its intended function, but 
instead is potentially promoting the increase of resistance. Some theories 
suggest that ribosomes display selective protein synthesis when bound by 
antibiotic [151]. Another theory suggests that there may be overexpression of 
ribosomal genes as a result of antibiotic exposure in order to dilute the effect of 
the drug molecules [152]. These may explain the peaks of expression of AcrB 
(Fig. 3.8). Further work will need to be carried out on the effect of translational 
inhibitors on antibiotic resistance mechanisms which utilise proteins, in order to 
be able to continue using such drugs safely and effectively in the foreseeable 
future.  
 
In chapter 2, although speculated, it was not possible to record any growth rate-
yield trade-offs as a result of a lack of data around the time points where the 
exponential phase would have occurred. In this chapter, due to regular 
intermittent OD measurements over 24 hours, it was possible to show that the 
growth rate increased significantly from 30oC to 37oC for all E. coli strains (Fig. 
3.5). However, trade-offs between growth rate and carrying capacity could not 
be revealed as the growth was continuous, and possibly even diauxic (Fig. 3.2 - 
3.4). Diauxic growth normally occurs when two sugars are present in the 
medium and are successively metabolised, undergoing two growth cycles as a 
result [147]. The minimal media used in these experiments contained only a 
limited amount of glucose (0.2% w/v) as the nutrient source, a common 
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concentration used to culture bacteria [153, 154, 155, 156].Therefore diauxic 
growth should not have occurred. However, studies in the past have shown that 
casamino acids can also be used as a carbon source once the main nutrient 
has been depleted [157, 158]. This may provide an explanation for the 
continued growth seen in Fig. 3.2 – 3.4. Thus, there is a possibility that the 
growth curves shown in chapter 2 (Fig. 2.2 – 2.6) may also not have reached 
stationary phase. Therefore if this experiment were to be repeated, it should be 
carried out over a longer duration to make sure that stationary phase is 
achieved, using a nitrogen source that is less likely to be metabolised.  
 
One of the questions that was posed during this research project was whether 
faster-growing E. coli cells are more susceptible to erythromycin than slower-
growing E. coli, specifically when the growth rate is manipulated by 
temperature. Previous studies have shown that slow-growing bacteria may 
display a level of tolerance to sudden antibiotic exposure [102, 103, 105]. 
However, this was not the case in Fig. 3.6, where slower-growing E. coli cells 
were shown to be actually more susceptible to erythromycin. Furthermore, 
higher expression levels of AcrB were not seen in cells with lower growth rates, 
and the peak expression of the pump component was in fact statistically the 
same at both temperatures (Fig. 3.8), unlike previous studies that have shown 
enhanced efflux for slower-growing cells [102, 103]. However it should be noted 
that the evolution of slow-growers and fast-growers within a bacterial population 
is postulated to have occurred in order to overcome the scarcity of nutrients in 
the environment [138]. Therefore inducing differences in growth rate using 
temperature over a period of 24 hours is most likely to not yield the same 
results. However, in a long-term evolutionary experiment, it may be interesting 








Chapter 4 – Concluding Remarks and Future Directions 
 
Antibiotic resistance is emerging at an alarming rate all over the world [1, 2, 3]. 
Although the blame is usually placed on factors such as poor treatment 
behaviour [1, 2, 3], other conditions, including environmental, may potentially 
contribute to this increase in incidence of resistance [80, 83, 86, 87, 88]. This 
research project aimed to provide preliminary insights into the relationship of 
temperature and the selection of antibiotic resistance mechanisms, specifically 
the efflux pump AcrAB-TolC. This was done by exposing E. coli to 0 – 70 µg/ 
mL of erythromycin at 30oC and 37oC and observing changes in the expression 
of AcrB, the antiporter component of AcrAB-TolC [53]. The results from these 
experiments show that an increase in temperature reduces the susceptibility of 
E. coli to erythromycin (Fig. 3.6), and that the concentrations at which selection 
of AcrB occurs also increase (Fig. 3.8). Ultimately, this supports the overall 
hypothesis of temperature being a potential selective pressure on antibiotic 
resistance. Furthermore, past studies along with the observations in this 
research project imply that the effect of temperature on drug susceptibility may 
be dependent on the strain and antibiotic being used [106, 107, 108, 149]. 
 
The temperatures 30oC and 37oC were originally chosen due to the range that 
exists around different parts of the body [92] and to mimic average seasonal 
temperatures seen around central latitudes such as China and India, where 
current literature has shown recent outbreaks of resistant infections [33, 98]. 
The implications of the findings from this research project may provide further 
insight in the way treatment can be tailored for certain temperatures to reduce 
the rate at which resistance is emerging e.g. one drug may be more effective 
and have less impact on resistance emergence when used on the skin or in a 
colder climate rather than for an internal infection of the body or in more 
temperate places. However, if this study were to be repeated, it may be useful 
to look at greater temperature ranges and their synergy with several classes of 
antibiotics against different pathogens, in order to pave the way to the possibility 
of temperature-dependent treatment of infections. 
 
For future work, it may be beneficial to investigate how temperature may be 
involved specifically in the long-term evolution of antibiotic resistance. This 
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would involve looking at how quickly bacteria are able to adapt to re-exposure 
to antibiotic, where the adaptation rate can be defined by the change in growth 
rate over time [159]. From this it may be possible to determine at which 
temperatures adaptation occurs more quickly and at which doses for specific 
antibiotics, i.e. the presence of evolutionary hotspots [68].  
 
Nonetheless, it is hoped that the findings of this research project provide a 
foundation into looking at environmental factors, such as temperature, and their 


































































Time (Hours) MG1655 vs eTB108 MG1655 vs AG100-A 
0 < 0.0001 < 0.0001 
1 1 1 
2 0.0163 0.0163 
3 0.0096 0.0096 
4 < 0.0001 < 0.0001 
5 0.3046 0.012 
6 0.0006 < 0.0001 
7 < 0.0001 < 0.0001 
8 0.7417 < 0.0001 
24 0.57 < 0.0001 
25 0.0087 < 0.0001 
26 0.8318 < 0.0001 
27 0.0087 < 0.0001 
28 0.0001 < 0.0001 
29 0.0014 < 0.0001 
30 0.0069 < 0.0001 
31 0.0004 < 0.0001 
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Time (Hours) MG1655 vs eTB108 MG1655 vs AG100-A 
0 1 1 
1 1 1 
2 0.1284 0.05 
3 < 0.0001 0.1284 
4 0.0006 < 0.0001 
5 0.0006 < 0.0001 
6 < 0.0001 < 0.0001 
7 < 0.0001 < 0.0001 
8 < 0.0001 < 0.0001 
24 0.1719 < 0.0001 
25 0.0011 < 0.0001 
26 0.1958 < 0.0001 
27 0.0082 < 0.0001 
28 0.0001 < 0.0001 
29 0.0028 < 0.0001 
30 0.7658 < 0.0001 







































2 < 0.0001 
3 < 0.0001 
4 < 0.0001 
5 < 0.0001 
6 < 0.0001 
7 < 0.0001 
8 < 0.0001 
24 < 0.0001 
25 < 0.0001 
26 < 0.0001 
27 < 0.0001 
28 < 0.0001 
29 < 0.0001 
30 < 0.0001 
31 < 0.0001 
Table S3: p-values for Fig. 2.4 
(MG1655 growth curves) 
obtained from unpaired t-test. 
 
Time (Hours) 30°C vs 37°C 
p-values 
0 < 0.0001 
1 1 
2 0.1423 
3 < 0.0001 
4 < 0.0001 
5 < 0.0001 
6 < 0.0001 
7 < 0.0001 







30 < 0.0001 
31 0.0003 
 
Table S4: p-values for Fig. 
2.5 (eTB108 growth curves) 

















Table S5: p-values for Fig. 2.6 (AG100-A growth curves) obtained from 
unpaired t-test. 
 











24 < 0.0001 
25 < 0.0001 
26 < 0.0001 
27 < 0.0001 
28 < 0.0001 
29 < 0.0001 
30 < 0.0001 






































Note: data for the 24th hour omitted 




Time (Hours) 30°C vs 37°C 
p-values 
6 < 0.0001 




30 < 0.0001 
Time (Hours) 30°C vs 37°C 
p-values 
6 < 0.0001 
8 < 0.0001 
24 1 
26 < 0.0001 
28 < 0.0001 
30 < 0.0001 





26 < 0.0001 
28 < 0.0001 
30 < 0.0001 
Table S6: p-values for Fig. 
2.7 (MG1655 OD-to-CFU/ mL 
conversion factors) obtained 
from unpaired t-test. 
Table S7:  p-values for Fig. 
2.8 (eTB108 OD-to-CFU/ mL 
conversion factors) obtained 
from unpaired t-test. 
Table S8: p-values for Fig. 2.9 
(AG100-A OD-to-CFU/ mL 
conversion factors) obtained 
from unpaired t-test. 
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Mean OD-to-CFU/ mL Conversion 
Factor Comparison 
p-value 
MG1655 30°C vs 37°C 0.0063 
eTB108 30°C vs 37°C 0.7567 
AG100-A 30°C vs 37°C 0.9915 
eTB108 (30°C) vs MG1655 (30°C) 0.735 
AG100-A (30°C) vs MG1655 (30°C) 0.0003 
Table S9: p-values for Fig. 2.10 (mean OD-to-CFU/ mL conversion factors) 
























































































































































Mean Optical Density (600nm)
30 Hours
Figure S1: Regressions of mean OD vs log CFU/ mL for E. coli strain MG1655 (WT) at 30oC per time point. Overnight culture of each strain diluted 1:1000 and 
allowed to incubate for 31 hours. For hours 6, 8, 24, 26, 28 and 30, OD and CFU/ mL recorded for half dilutions to obtain equation of line i.e. OD-to-CFU/ mL 
conversion factors. Data points include biological and technical triplicate, where error bars represent standard error of the mean. Error bars may be small and 
hidden behind data points. 
 
Figure S1: Linear regressions of mean OD vs CFU/ mL for E. coli strain MG1655 (WT) at 30oC per time point. Overnight culture of each strain diluted at 1:1000 
and allowed to incubate for 31 hours. For hours 6, 8, 24, 26, 28 and 30, CFU/ mL recorded for half dilutions to obtain equation of line i.e. OD-to-CFU/ mL 
conversion factors. Data points include biological and technical triplicate, where error bars represent standard error of the mean. 
 
Figure S1: Linear regressions of mean OD vs CFU/ mL for E. coli strain MG1655 (WT) at 30oC per time point. Overnight culture of each strain diluted at 1:1000 
and allowed to incubate for 31 hours. For hours 6, 8, 24, 26, 28 and 30, CFU/ mL recorded for half dilutions to obtain equation of line i.e. OD-to-CFU/ mL 
























































































































































Mean Optical Density (600nm)
26 Hours
Figure S2: Regressions of mean OD vs log CFU/ mL for E. coli strain MG1655 (WT) at 37oC per time point. Overnight culture of each strain diluted 1:1000 and 
allowed to incubate for 31 hours. For hours 6, 8, 24, 26, 28 and 30, OD and CFU/ mL recorded for half dilutions to obtain equation of line i.e. OD-to-CFU/ mL 
conversion factors. Data points include biological and technical triplicate, where error bars represent standard error of the mean. Error bars may be small and 
hidden behind data points. 
 
Figure S2: Linear regressions of mean OD vs CFU/ mL for E. coli strain MG1655 (WT) at 37oC per time point. Overnight culture of each strain diluted at 1:1000 
and allowed to incubate for 31 hours. For hours 6, 8, 24, 26, 28 and 30, CFU/ mL recorded for half dilutions to obtain equation of line i.e. OD-to-CFU/ mL 
conversion factors. Data points include biological and technical triplicate, where error bars represent standard error of the mean. 
 
Figure S2: Linear regressions of mean OD vs CFU/ mL for E. coli strain MG1655 (WT) at 37oC per time point. Overnight culture of each strain diluted at 1:1000 
and allowed to incubate for 31 hours. For hours 6, 8, 24, 26, 28 and 30, CFU/ mL recorded for half dilutions to obtain equation of line i.e. OD-to-CFU/ mL 

























































































































































Mean Optical Density (600nm)
30 Hours
Figure S3: Regressions of mean OD vs log CFU/ mL for E. coli strain eTB108 (acrB-sfGFP) at 30oC per time point. Overnight culture of each strain diluted 
1:1000 and allowed to incubate for 31 hours. For hours 6, 8, 24, 26, 28 and 30, OD and CFU/ mL recorded for half dilutions to obtain equation of line i.e. OD-to-
CFU/ mL conversion factors. Data points include biological and technical triplicate, where error bars represent standard error of the mean. Error bars may be 
small and hidden behind data points. 
 
Figure S3: Linear regressions of mean OD vs CFU/ mL for E. coli strain eTB108 (acrB-sfGFP) at 30oC per time point. Overnight culture of each strain diluted at 
1:1000 and allowed to incubate for 31 hours. For hours 6, 8, 24, 26, 28 and 30, CFU/ mL recorded for half dilutions to obtain equation of line i.e. OD-to-CFU/ mL 
conversion factors. Data points include biological and technical triplicate, where error bars represent standard error of the mean. 
 
Figure S3: Linear regressions of mean OD vs CFU/ mL for E. coli strain eTB108 (acrB-sfGFP) at 30oC per time point. Overnight culture of each strain diluted at 
1:1000 and allowed to incubate for 31 hours. For hours 6, 8, 24, 26, 28 and 30, CFU/ mL recorded for half dilutions to obtain equation of line i.e. OD-to-CFU/ mL 
























































































































































Mean Optical Density (600nm)
30 Hours
Figure S4: Regressions of mean OD vs log CFU/ mL for E. coli strain eTB108 (acrB-sfGFP) at 37oC per time point. Overnight culture of each strain diluted 
1:1000 and allowed to incubate for 31 hours. For hours 6, 8, 24, 26, 28 and 30, OD and CFU/ mL recorded for half dilutions to obtain equation of line i.e. OD-to-
CFU/ mL conversion factors. Data points include biological and technical triplicate, where error bars represent standard error of the mean. Error bars may be 
small and hidden behind data points. 
 
Figure S4: Linear regressions of mean OD vs CFU/ mL for E. coli strain eTB108 (acrB-sfGFP) at 37oC per time point. Overnight culture of each strain diluted at 
1:1000 and allowed to incubate for 31 hours. For hours 6, 8, 24, 26, 28 and 30, CFU/ mL recorded for half dilutions to obtain equation of line i.e. OD-to-CFU/ mL 
conversion factors. Data points include biological and technical triplicate, where error bars represent standard error of the mean. 
 
Figure S4: Linear regressions of mean OD vs CFU/ mL for E. coli strain eTB108 (acrB-sfGFP) at 37oC per time point. Overnight culture of each strain diluted at 
1:1000 and allowed to incubate for 31 hours. For hours 6, 8, 24, 26, 28 and 30, CFU/ mL recorded for half dilutions to obtain equation of line i.e. OD-to-CFU/ mL 
























































































































































Mean Optical Density (600nm)
30 Hours
Figure S5: Regressions of mean OD vs log CFU/ mL for E. coli strain AG100-A (∆acrAB) at 30oC per time point. Overnight culture of each strain diluted 1:1000 
and allowed to incubate for 31 hours. For hours 6, 8, 24, 26, 28 and 30, OD and CFU/ mL recorded for half dilutions to obtain equation of line i.e. OD-to-CFU/ mL 
conversion factors. Data points include biological and technical triplicate, where error bars represent standard error of the mean. Error bars may be small and 
hidden behind data points. 
 
Figure S5: Linear regressions of mean OD vs CFU/ mL for E. coli strain AG100-A (∆acrAB) at 30oC per time point. Overnight culture of each strain diluted at 
1:1000 and allowed to incubate for 31 hours. For hours 6, 8, 24, 26, 28 and 30, CFU/ mL recorded for half dilutions to obtain equation of line i.e. OD-to-CFU/ mL 
conversion factors. Data points include biological and technical triplicate, where error bars represent standard error of the mean. 
 
Figure S5: Linear regressions of mean OD vs CFU/ mL for E. coli strain AG100-A (∆acrAB) at 30oC per time point. Overnight culture of each strain diluted at 
1:1000 and allowed to incubate for 31 hours. For hours 6, 8, 24, 26, 28 and 30, CFU/ mL recorded for half dilutions to obtain equation of line i.e. OD-to-CFU/ mL 






































































































































Mean Optical Density (600nm)
30 Hours
Figure S6: Regressions of mean OD vs log CFU/ mL for E. coli strain AG100-A (∆acrAB) at 37oC per time point. Overnight culture of each strain diluted 1:1000 
and allowed to incubate for 31 hours. For hours 6, 8, 26, 28 and 30, OD and CFU/ mL recorded for half dilutions to obtain equation of line i.e. OD-to-CFU/ mL 
conversion factors. Observations at 24 hours have been omitted due to error. Data points include biological and technical triplicate, where error bars represent 
standard error of the mean. Error bars may be small and hidden behind data points. 
 
Figure S6: Linear regressions of mean OD vs CFU/ mL for E. coli strain AG100-A (∆acrAB) at 37oC per time point. Overnight culture of each strain diluted at 
1:1000 and allowed to incubate for 31 hours. For hours 6, 8, 24, 26, 28 and 30, CFU/ mL recorded for half dilutions to obtain equation of line i.e. OD-to-CFU/ mL 
conversion factors. Data points include biological and technical triplicate, where error bars represent standard error of the mean. 
 
Figure S6: Linear regressions of mean OD vs CFU/ mL for E. coli strain AG100-A (∆acrAB) at 37oC per time point. Overnight culture of each strain diluted at 
1:1000 and allowed to incubate for 31 hours. For hours 6, 8, 24, 26, 28 and 30, CFU/ mL recorded for half dilutions to obtain equation of line i.e. OD-to-CFU/ mL 


















 MG1655 eTB108 AG100-A 















6 9 0.8298 20 0.9781 6 0.866 10 0.9718 2 0.7003 3 0.8116 
8 8 0.9586 20 0.9698 8 0.9248 20 0.9694 8 0.3694 10 0.9137 
24 20 0.9969 20 0.9919 20 0.9021 20 0.9748 2 0.956 - - 
26 10 0.9738 40 0.7945 20 0.917 20 0.9535 2 0.9892 0.8 0.998 
28 20 0.9857 30 0.9902 20 0.9723 20 0.9729 2 0.9995 0.8 0.9742 
30 20 0.97 30 0.954 20 0.9742 10 0.9806 2 0.9171 0.5 0.9662 
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